ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-CDH17/Exatecan Antibody-drug Conjugate ARR-217

Also written as “MRG007” and “MRG007 and Bevacizumab”.

Its studies are mostly in Colorectal Neoplasms, led by ArriVent BioPharma.

Furthest: phase 1, since Jun 26, 20251 company-led study, 1 open or runningNext primary completion: Mar 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
ArriVent BioPharma11 open or runningphase 1since Jun 26, 2025Jun 26, 2025Mar 2028phase 1 · NCT07066657

Also a collaborator on its studies: Lepu Biopharma.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 26, 2025First study: phase 1 study in Colorectal NeoplasmsFirst studyNCT07066657 · 572 planned · United States, China

Ahead

  1. Mar 2028Primary completion: phase 1 study in Colorectal NeoplasmsNCT07066657

TargetBeta

CDH17 →read by rule
“An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the tumor-associated antigen (TAA) cadherin-17 (CDH17) site-specifically ”NCIt, by rule

Other programs on CDH17

ProgramCompanyFurthest phaseStudies
Anti-CDH17 Antibody-drug Conjugate HS-20110Hansoh Pharmaceutical Groupphase 22
Anti-CDH17/MF-6 Antibody-drug Conjugate 7MW4911ruleMabwell (Shanghai) Biosciencephase 22
AMT-676rulemultitude-therapeutics-incphase 22
Anti-CDH17/Topoisomerase I Inhibitor Antibody-drug Conjugate DB-1324ruledualitybio-incphase 21
LM-350Sino Biopharmaceuticalphase 21
Anti-CDH17 Antibody-drug Conjugate YL217ruleMediLink Therapeutics (Suzhou)phase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07066657Colorectal Neoplasms · United States, China1RecruitingMar 2028572

How it is read

Names in the registry

  • “MRG007”, 1 entry
  • “MRG007 and Bevacizumab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.